Ann Louise Walker

USPTO Granted Patents = 32 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 4.7

ph-index = 9

Forward Citations = 165(Granted Patents)

Location History:

Hertfordshire, GB (2005)
Stevenage, GB (1998 - 2020)

Company Filing History:

Smithkline Beecham Corporation

patents

4. 5 out of 230

Glaxosmithkline Intellectual Property Development Limited

patents

5. 1 out of 134

University College Cardiff Consultants Limited

patents

6. 1 out of 168

The University of Edinburgh

patents

Years Active: 1998-2020

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

2. 10611756 - Method of treating pancreatitis using 1,4-benzoxazine derivatives (2020-04-07),

3. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

4. 10273232 - 3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors (2019-04-30),

5. 10246447 - 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors (2019-04-02),

6. 10039755 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2018-08-07),

7. 9932328 - 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors (2018-04-03),

8. 9833449 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2017-12-05),

9. 9518054 - 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors (2016-12-13),

10. 9315487 - Tetrahydroquinoline derivatives useful as bromodomain inhibitors (2016-04-19),

11. 9127003 - 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors (2015-09-08),

12. 8575204 - Nicotinamide derivates useful as P38 inhibitors (2013-11-05),

13. 8252818 - Nicotinamide derivatives useful as P38 inhibitors (2012-08-28),

14. 7838540 - 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors (2010-11-23),

15. 7732622 - Naphthalene derivatives (2010-06-08),

Title: The Innovative Journey of Ann Louise Walker

Introduction

Ann Louise Walker, an accomplished inventor based in Stevenage, GB, has made significant contributions to the field of pharmaceutical innovations. With a remarkable 32 patents to her name, Walker's research primarily focuses on developing new therapeutic compounds that target various medical conditions.

Latest Patents

Among her latest innovations is the patent for "Benzoimidazole derivatives as PAD4 inhibitors." This groundbreaking invention presents compounds that may serve as potential treatments for a range of disorders, including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. Additionally, she has developed a method for treating pancreatitis utilizing 1,4-benzoxazine derivatives. This patent outlines methods for treating pancreatitis and kidney diseases through the administration of 6-chlorobenzoxazine compounds, offering new hope for those affected by these conditions.

Career Highlights

Walker has been affiliated with prominent companies such as Glaxo Group Limited and GlaxoSmithKline LLC, where she has honed her expertise in drug development and innovation. Her work has played a pivotal role in advancing the understanding and treatment of complex health challenges.

Collaborations

Throughout her career, Ann Louise Walker has collaborated with several esteemed colleagues, including Paul Bamborough and Nicola Mary Aston. These partnerships have enriched her research endeavors and contributed to the successful development of her patented technologies.

Conclusion

In summary, Ann Louise Walker stands out as a visionary inventor whose work continues to impact the pharmaceutical landscape. Her dedication to creating innovative solutions for medical disorders exemplifies the spirit of invention and highlights the importance of collaboration in the field of research and development. As she progresses in her career, the industry eagerly anticipates her future contributions and the potential breakthroughs that may arise from her ongoing research.

This text is generated by artificial intelligence and may not be accurate.